ARmallissa

ARmallissa is a technology and medical solutions company headquartered in Zurich, Switzerland, specializing in artificial intelligence–driven diagnostic tools. Since its establishment, it has focused on improving early detection of diseases through advanced image analysis. The company’s brand is recognizable for its integrated software and hardware solutions that are employed in clinical environments worldwide.

ARmallissa was founded in 2012 by Dr. Petra Müller and engineer Lars Berg, who previously worked for MedTech Solutions. Early funding came from the Swiss National Science Foundation and a series A private investment round. The first public listing occurred on the Swiss Exchange in 2017, shortly after the company introduced its flagship product, MallVision, for MRI scan interpretation.

MallVision employs convolutional neural networks trained on millions of annotated scans to identify anomalies such as tumours and vascular lesions. The platform can integrate with existing PACS systems, providing real‑time overlays and risk scores. In 2020, ARmallissa released a cloud‑based extension, enabling remote analysis for low‑resourced hospitals and earning a grant from the European Union for digital health innovation.

The company has partnered with leading hospitals including University Hospital Zurich and Charité – Universitätsmedizin Berlin, and maintained research agreements with ETH Zurich and the University of Cambridge. ARmallissa’s products are marketed in over 40 countries, with a distribution network that includes both direct sales and channel partners. Its annual revenue surpassed 120 million CHF in 2023, supported by a workforce of 350 employees.

Looking ahead, ARmallissa plans to expand its portfolio into genomic data integration, announced plans for an AI‑driven pathology module in 2025, and seeks regulatory approval in the United States. The company remains committed to evidence‑based development, engaging in continuous clinical trials to validate each new feature. Overall, ARmallissa is positioned as a notable player in the intersection of medical imaging and artificial intelligence, contributing to improved diagnostic accuracy and patient outcomes.